杭州天龙药业

Hangzhou Tianlong Pharmaceutical Co., Ltd. is a Chinese biotechnology company specializing in the research, development, and industrialization of nucleic acid-based therapeutics. Established in 2009 and acquired by Yuekang Pharmaceutical Group in 2021, the company serves as Yuekang's core platform for oligonucleotide, small interfering RNA (siRNA), and mRNA drug development. Its lead candidate, CT102, is a first-in-class antisense oligonucleotide (ASO) targeting the insulin-like growth factor 1 receptor (IGF1R) for the treatment of primary hepatocellular carcinoma, currently in Phase 2 clinical trials. Additionally, the company is advancing a robust pipeline of liver-targeted siRNA therapies and mRNA vaccines utilizing proprietary delivery technologies, addressing major chronic conditions such as hypertension, hypercholesterolemia, chronic hepatitis B, and respiratory infections.